Human alpha – Fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer

Crandall BF: Alpha-fetoprotein: A review. CRC Rev Clin Lab Sci 15: 127-185, 1981

Deutsch HF: Chemistry and biology of a a-fetoprotein. Adv Cancer Res 56: 253-312, 1991

Mizejewski GJ: Alpha-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure. Proc Soc Exptl Biol Med 215: 333-362, 1997

Mizejewski GJ: The phylogeny of alpha-fetoprotein in vertebrates: survey of biochemical and physiological data. Crit Rev Eukaryot Gene Expr 5: 281-316, 1995

Nishi S, Shahbazzadeb D, Azuma M, Sakai M: Estrogenbinding site of rat alpha-fetoprotein. Tumor Biol 14: 234, 1993

Leffert HI, Sell S: Alpha-fetoprotein biosynthesis during the growth cycle of differentiated fetal rat hepatocytes in primary monolayer culture. J Cell Biol 61: 823-829, 1974

Toder V, BlandM. Gold-Gefter L, Nebel J: The effect of alphafetoprotein on the growth of placental cells in vitro. Placenta 4: 79-86, 1983

Hamel S, Hoskin DW, Hooper DC, Murgita RA: Phenotype and function of bone marrow-derived T and non-T cells activated in vitro by alpha-fetoprotein. In: Mizejewski GJ, Jacobson HI (eds). Biological Activities of Alpha-fetoprotein. CRC Press, Florida, 1987, pp 167-177

Leal JA, May JV, Keel BA: Human alpha-fetoprotein enhances epidermal growth factor proliferation activity upon porcine granulosa cells in monolayer culture. Endocrinology 126: 669-671, 1980

Keel BA, Eddy KB, Cho S, May JV: Synergistic action of purified a-fetoprotein and growth factors on the proliferation of porcine granulosa cells in monolayer culture. Endocrinology 129: 217-225, 1991

Mizejewski GJ, Warner AS: Alpha-fetoprotein can regulate growth in the uterus of the immature and adult ovariectomized mouse. J Reprod Fertil 85: 177-185, 1989

Mizejewski GJ, Keenan JF, Setty RP: Separation of the estrogen-activated growth regulatory forms of alphafetoprotein in mouse amniotic fluid. Biol Reprod 42: 887-898, 1990

Sonnenschein C, Ucci AA, Soto AM: Growth inhibition of estrogen-sensitive rat mammary tumors. Effect of an alphafetoprotein-secreting hepatoma. J Natl Cancer Instit 64: 1147-1152, 1980

Bennett JA, Semeniuk DT, Jacobson HI, Murgita RA: Similarity between natural and recombinant human alpha-fetoprotein as inhibitors of estrogen-dependent breast cancer growth. Breast Cancer Res Treat 48: 169-179, 1997

Bennett JA, Zhu SJ, Pagano-Mirarchi A, Kellom TA, Jacobson HI: Alpha-fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts. Clin Cancer Res 4: 2877-2884, 1998

Dudich E, Semenkova L, Gorbatova E, Dudich I, Khromykh L, Tatulov E, Grechko G, Sukhikh G: Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. Tumor Biol 19: 30-40, 1998

Mizejewski GJ, Vonnegut M, Jacobson HI: Estradiol-activated alpha-fetoprotein suppress the uterotropic response to estrogens. Proc Natl Acad Sci USA 80: 2733, 2737, 1983

Mizejewski GJ, Vonnegut M, Jacobson HI: Studies of the intrinsic antiuterotropic activity of murine alpha-fetoprotein. Tumor Biol 7: 19-28, 1986

Jacobson HI, Bennett JA, Mizejewski GJ: Inhibition of estrogen-dependent breast cancer growth by a reaction product of a-fetoprotein and estradiol. Cancer Res 50: 415-420, 1990

Butterstein G, Mizejewski GJ: Alpha-fetoprotein inhibits frog metamorphosis: Implications for protein motif conservation. J Comp Biochem Physiol 124: 39-45, 1999

Jacobson HI, Marotta D, Mizejewski GJ, Bennett JA, Anderson TT: Estradiol-induced changes in spectral and biologic properties of alpha-fetoprotein. Tumor Biology 11: 104-105, 1990

Bennett JA, Mizejewski GJ, Allen SHG, Zhu SJ, Jacobson HI: Transformation of alpha-fetoprotein to a negative regulator of estrogen-dependent growth by ligands of the steroid/thyroid hormone receptor superfamily. 18th International Congress, J Cancer Res Clin Oncol 34: 244, 1993

Festin SM, Bennett JA, Fletcher PW, Jacobson HI, Shaye DD, Andersen TT: The recombinant third domain of human alpha-fetoprotein retains the antiestrotrophic activity found in the full-length molecule. Biochemie Biophysica Acta 24789: 307-314, 1999

Uversky VN, Narizhneva NV, Ivanova TV, Kirkitadze MD, Tomashevski AY: Ligand-free form of human alphafetoprotein: evidence for the molten globule state. FEBS Lett. 410: 280-284, 1997

Uversky VN, Narizhneva NV, Ivanova TV, Tomashevski AY: Rigidity of human alpha-fetoprotein tertiary structure is under ligand control. Biochem. 36: 13638-13645, 1997

Uversky VN, Kirkistadze MD, Narizhneva NV, Potekhin SA, Tomashevski AV: Structural properties of AFP from human cord serum: the protein molecule at low pH possesses all the properties of the molten globule. FEBS Lett. 364: 165-167, 1996

Mizejewski GJ, Dias JA, Hauer CR, Henrikson KP, Gierthy JF: Alpha-fetoprotein derived synthetic peptides: Assay of an estrogen-modifying regulatory segment. Mol Cellular Endocrinol 118: 15-23, 1996

Richardson BE, Hulka BS, David Peck JL, Hughes CL, van den Berg BJ, Christianson RE, Calvin JA: Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 148: 719-727, 1998

Vakharia D, Gierthy J: Rapid assay for oestrogen receptor binding to PCB metabolites. Toxicology in vitro 13: 275-282

Parsons DF, Foley J, Marko M, Wanson, K: Immediate ascites conversion of mammary tumors induced in NYLR/Nya mice by 7, 12-dimethylbenz-[a] anthracene and urethane feeding and by forced breeding. Cancer Invest. 4: 109-126, 1986

Parsons DF, Marko M, Sacks PG, Foley BS: Targeting of peritoneum by the small numbers of isogeneic and allogeneic ascites carcinoma cells that infiltrate or attach to peritoneum during ascites growth. Cancer Invest 8: 483-491, 1990

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990

Vakharia DD, Dias JA, Thakur AN, Andersen TT, O'shea A: Mapping of an assembled epitope of human hFSHb utilizing synthetic peptides, hormone-receptor inhibition, and monoclonal antibodies. Endocrinology 127: 658-666, 1990

Pearson WR: Rapid and sensitive sequence comparison with FASTP and FASTA. Methods in Enzymology 183: 63-98, 1990

Wurtz J-M, Bourguet W, Renaud J-P, Vivat V, Chambon P, Moras D, Gronemeyer H: A canonical structure for the ligandbinding domain of nuclear receptors. Nature Struc Biol 3: 87-94, 1996

Nguyen JT, Turck CW, Cohen FE, Zuckermann RN, Lim WA: Exploiting the basis of proline recognition by SH3 and WW domains: Design of N-substituted inhibitors. Science 282: 2088-2092, 1998

O'Malley B, Schrader WT, Mani S, Smith C, Weigel NL, Conneely OM, Clark JH: An alternative ligand-independent pathway for activation of steroid receptors. Rec Progr Hor Res 50: 333-347, 1995

Mizejewski GJ, Dauphinee MJ: An alpha-fetoprotein-derived peptide can inhibit growth and induce cytostasis in multiple tumor types both in vitro and in vivo. Clin Cancer Res 5: Abst# 0696, 1999

Razandi M, Pedram A, Greene GL, Levin ER: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERa and ERb expressed in Chinese hamster ovary cells. Mol Endocrinol 13: 307-319, 1999

Uriel J, Bouillon D, Aussel C, Dupiers M: Alpha-fetoprotein: The major high-affinity estrogen binder in rat uterine cytosols. Proc Natl Acad Sci USA 73: 1452-1456, 1976

Uriel J, de Nechaud B, Dupiers M: Estrogen-binding properties of rat, mouse and man fetospecific serum proteins. Demonstration by immuno-autoradiographic methods. Biochem Biophys Res Comm 46: 1175-1180, 1972

Uriel J, Bouillon D, Dupiers M: Affinity chromatography of human, rat and mouse alpha-fetoprotein on estradiolsepharose adsorbents. FEBS Lett 53: 305-308, 1975

Tatarinov YS, Terentiev AA, Moldogazieva AK, Tagirova AK: Human alpha-fetoprotein and its purification by chromatography on immobilized estrogens. Tumor Biol 12: 125-130, 1991

Uversky VN, Narizhneva NV, Kirschstein O, Winter S, Lober G: Conformational transitions provoked by organic solvents in b-lactoglobulin: can a molten globule like intermediate be induced by the decrease in dielectric constant. Folding & Design 2: 163-172, 1997

Trinder D, Phillips PA, Stephenson JM, Risvanis J, Aminian A, Adam W, Cooper M, Johnston CI: Vasopressin V1 and V2 receptors in diabetes mellitus. Am J Physiol 266: E217-223, 1994

Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG, Powell DR: FKHR binds the insulin response element in insulin-like growth factor binding protein-1 promoter. Endocrinology 140: 3140-3146, 1999

Rule AH, Sligeris MA, Farber M, Britton G, Vandervoorde J: Relation of glucose to alpha-fetoprotein in amniotic fluid. Obstet Gynecol 57: 310-312, 1981

Wald NJ, Cuckle H, Boreham J, Stirrat GM, Turnbull AC: Maternal serum alpha-fetoprotein and diabetes mellitus. Br J Obstet Gynecol 86: 101-105, 1979

Bei R, Budillon A, Reale MG, Capuano G, Pomponi D, Budillon G, Frati L, Muraro R: Cryptic epitopes on AFP induces spontaneous immune response in hepatocellular carcinoma, liver cirrhosis and heptatitis. Cancer Res 59: 5471-5474, 1999

Nustad K, Paus E, Kierulf B, Bomer P: Specificity and affinity y of 30 monoclonal antibodies against alpha-fetoprotein. Tumor Biol 19: 293-300, 1998

Yakimenko EF, Karamova ER, Goussev AI, Hilgers J, Abelev GI, Yazova AK: Epitope mapping of human alpha-fetoprotein. Tumor Biol 19: 301-309, 1998

Lipworth L, Hsieh C-C, Wide L, Ekbom A, Yu S-Z, Yu G-P, Xu B, Hellerstein S, Carlstrom K, Trichopoulos D, Adami HO: Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai, China) of breast cancer. Br J Cancer 79: 7-12, 1999

Melbye M, Wohlfahrt J, Lei U, Norgaard-Pedersen B, Mouridsen HT, Lambe M, Michels KB: Alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J Natl Cancer Institute 92: 1001-1005, 2000